Cancers, Год журнала: 2025, Номер 17(8), С. 1283 - 1283

Опубликована: Апрель 10, 2025

Bladder cancer (BCa) is a highly recurrent malignancy that requires sensitive and noninvasive diagnostic predictive markers. Conventional tools, such as cystoscopy urine cytology, are far from ideal in terms of sensitivity, specificity, patient compliance. In this narrative review, the development novel urinary markers for diagnosis BCa highlighted, with focus on their application clinical arena, detection accuracy, future potential. An extensive analysis new biomarkers, including proteinuria-based tests, DNA methylation RNA-based molecular panels, has been conducted. Various Cxbladder®, EpiCheck®, UroSEEK, clinically valid. Urinary biomarkers provide promising alternative traditional diagnostics enhanced specificity possibility early diagnosis. Future research should large-scale validation standardization to facilitate use routine practice.

Язык: Английский